Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNYBiotechnology
-$6.27 today
- Market cap
- $20.01B
- Beta
- 0.27
- P/E (TTM)
- 63.6
- EPS (TTM)
- $4.34
Volume 2.52M
Average 1.11M
ALNY Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $347.92M rose 7.6% year over year, behind the +22.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.9% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- Selling, general & admin amounted to 32.6% of revenue in FY2025, down 10.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 21 analysts of $2.91B (+140.3%) for the fiscal year ending Dec 2026, a step up from the +24.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $347.92M+7.9% QoQ
- Last fiscal yearDec 2025
- $1.21B+24.1% YoY
- LTMJun 2026
- $1.32B+22.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 1.21B USD
- Year-over-year change
- +24.1%
- 4-year CAGR
- +18.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.21B | +24.1% |
| FY2024 | 2024-12-31 | 975.53M | +22.6% |
| FY2023 | 2023-12-31 | 795.65M | +3.2% |
| FY2022 | 2022-12-31 | 770.66M | +24.2% |
| FY2021 | 2021-12-31 | 620.64M | — |
Selling, General & Admin vs competitors
How ALNY compares with its peers on the latest reported figures
- ALNY's LTM Jun 2026 selling, general & admin of $1.32B is the highest of the 6 companies compared; the peer median is $157.94M.
- Its year-over-year change of +22.1% is the 4th highest of 5, against a peer median of +44.4%.
- Selling, general & admin amounts to 27.4% of revenue for ALNY, versus a peer median of 110.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.32B | +22.1% | +16.3% | 27.4% | |
| LTM Sep 2026 | $584.98M | +66.3% | +37.9% | 61.0% | |
| LTM Sep 2026 | $201.04M | +64.9% | +30.5% | 44.6% | |
| LTM Mar 2026 | $157.94M | +14.5% | +9.9% | 239.0% | |
| LTM Mar 2026 | $79.08M | +23.9% | +14.3% | 110.1% | |
| LTM Mar 2026 | $23.59M | — | +2.2% | 2560.2% | |
| Peer median (excluding ALNY) | $157.94M | +44.4% | +14.3% | 110.1% | |
Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 844.29M | 1.04B | 1.83B | 2.25B | 3.71B |
| Cost of Revenue | 140.14M | 168.82M | 310.41M | 323.37M | 677.17M |
| Gross Profit | 704.14M | 868.6M | 1.52B | 1.92B | 3.04B |
| Gross Margin | 83.4% | 83.7% | 83.0% | 85.6% | 81.8% |
| Research & Development | 792.16M | 883.02M | 1B | 1.13B | 1.32B |
| Selling, General & Admin | 620.64M | 770.66M | 795.65M | 975.53M | 1.21B |
| Operating Expenses | 1.41B | 1.65B | 1.8B | 2.1B | 2.54B |
| Depreciation & Amortization | 47.57M | 44.47M | 54.05M | 56.67M | 55.66M |
| EBITDA | (661.56M) | (926.56M) | (258.24M) | (178.85M) | 631.44M |
| EBITDA Margin | -78.4% | -89.3% | -14.1% | -8.0% | 17.0% |
| Operating Income | (708.65M) | (785.07M) | (282.18M) | (176.89M) | 501.58M |
| Operating Margin | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% |
| Interest Income | 1.58M | 24.81M | 95.56M | 121.99M | 111.47M |
| Interest Expense | 143.02M | 155.97M | 121.22M | 141.86M | 252.63M |
| Other Income / Expenses | (143.49M) | (341.92M) | (151.34M) | (200.49M) | (178.43M) |
| Income Before Tax | (852.14M) | (1.13B) | (433.52M) | (377.38M) | 323.15M |
| Pre-Tax Margin | -100.9% | -108.6% | -23.7% | -16.8% | 8.7% |
| Income Tax Expense | 680K | 4.16M | 6.73M | (99.22M) | 9.41M |
| Net Income | (852.82M) | (1.13B) | (440.24M) | (278.16M) | 313.75M |
| Net Margin | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| EPS (Basic) | (7.20) | (9.30) | (3.52) | (2.18) | 2.39 |
| EPS (Diluted) | (7.20) | (9.30) | (3.52) | (2.18) | 2.33 |
| Weighted Avg Shares | 118.45M | 121.69M | 124.91M | 127.65M | 131M |
| Weighted Avg Shares (Diluted) | 118.45M | 121.69M | 124.91M | 127.65M | 134.68M |
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
Intrinsic Alpha fair value
Locked
Current Price
$149.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.